Luciferase Reporter Cell Line - OVCAR-3

The OVCAR-3 cell line is a well-characterized human ovarian carcinoma model, originally isolated in 1982 from the malignant ascites of a patient suffering from progressive adenocarcinoma of the ovary. Growing as an adherent epithelial monolayer, this line is particularly valuable due to its inherent clinical resistance to standard chemotherapeutics, alongside its active expression of both estrogen and androgen receptors. The Luciferase Reporter Cell Line - OVCAR-3 significantly enhances this established oncological model. Through stable lentiviral transduction, the cells are engineered to constitutively express the firefly luciferase enzyme. This genetic integration ensures that the cells emit a consistent, robust bioluminescent signal upon exposure to the substrate D-luciferin. Crucially, this targeted modification transforms the parental line into a highly sensitive, quantifiable tracking tool without altering its foundational malignant behavior, receptor status, or unique chemoresistance profile.

Leveraging these distinct malignant properties, the reporter line serves as a cornerstone for pre-clinical ovarian cancer research. In vitro, the constitutive luminescence facilitates high-throughput cell viability and cytotoxicity assays. Researchers can rapidly screen novel pharmacological compounds, immunotherapies, and combination treatments against drug-resistant cancer cells, using the bioluminescent readout as a direct, accurate proxy for cellular survival and proliferation. In vivo, these engineered cells are critical for establishing highly translational subcutaneous and orthotopic xenograft mouse models. By implanting the luciferase-expressing cells, scientists can utilize non-invasive bioluminescence imaging to track initial tumor engraftment, monitor metastatic spread throughout the peritoneal cavity, and evaluate the dynamic efficacy of experimental treatments in living animals. This longitudinal tracking yields precise spatial and temporal data while significantly reducing the number of animal subjects required, ultimately accelerating the development of targeted interventions for aggressive ovarian carcinomas.